Jupiter, F.L. — June 11, 2026 — Leads & Copy — Human Continuum Inc. has secured $5.13 million in seed financing to advance its exosome-based therapeutics and diagnostics platform, focusing on longevity and regenerative medicine. The funding underscores growing shareholder support for the company’s mission to develop next-generation biologic solutions for various health issues through exosome therapies.
The company’s exosome platform aims to leverage regenerative signals from platelets for a minimally invasive, scalable, and standardized approach to regenerative medicine. This technology addresses the need for advanced therapies, particularly for musculoskeletal diseases like osteoarthritis, which affect over 60 million adults in the U.S. alone.
Human Continuum is also developing topical exosome dermatologic formulations, point-of-care exosome diagnostic technology, and an exosomal biomarker panel for the longitudinal monitoring of orthopedic diseases. These initiatives contribute to a comprehensive platform designed to support human health and longevity.
“Human Continuum reflects not only our identity as a company but the foundation of our mission: advancing long-term health and longevity,” said Dr. Sean Law, MD, MBA, Chief Executive Officer and Board Member of Human Continuum. “The support our shareholders have demonstrated through this raise is critical to that mission and the work ahead of us. The capital will allow us to move forward on several key fronts, including expanding our technical team and strengthening our research and development capabilities. We are focused on ensuring HC is well positioned to contribute meaningfully to this exciting sector.”
Dr. Omar K. Sial, Ph.D., Chief Scientific Officer of Human Continuum, added, “This raise represents a meaningful step forward for the Company and will allow us to accelerate the development of a fully integrated exosome-based therapeutics platform. The timing is significant, as we are making tangible progress across several key development pipelines. We are grateful for the continued confidence our shareholders have placed in the Company and in the scientific excellence underpinning our team’s work.”
About Human Continuum Inc.:
Human Continuum Inc. is developing a platform of exosome-based therapeutics and diagnostics for longevity, orthopedics, aesthetics, and dermatology. Their lead program investigates regenerative signaling pathways for inflammatory biomarkers. The company is also advancing an investigational device for musculoskeletal conditions, topical plant-derived exosome formulations for skin health, point-of-care diagnostics for joint-infection detection, and exosomal biomarker panels for orthopedic disease monitoring.
Source: Human Continuum Inc.
